

## Alpha-crystallin B chain/CRYAB Protein, Human (His)

|                          |   |
|--------------------------|---|
| <b>Cat. No.:</b>         | HY-P7873  |
| <b>Synonyms:</b>         | rHuAlpha-crystallin B chain/CRYAB, His; Alpha-Crystallin B Chain; Alpha(B)-Crystallin; Heat Shock Protein Beta-5; HspB5; Renal Carcinoma Antigen NY-REN-27; Rosenthal Fiber Component; CRYAB; CRYA2 |
| <b>Species:</b>          | Human   |
| <b>Source:</b>           | E. coli   |
| <b>Accession:</b>        | P02511 (M1-K175)  |
| <b>Gene ID:</b>          | 1410  |
| <b>Molecular Weight:</b> | Approximately 24 kDa  |

### PROPERTIES

|                                |   |
|--------------------------------|---|
| <b>AA Sequence</b>             | <pre> MDIAIHHPI   RRPFFPFHSP   SRLFDQFFGE   HLLSDLFPT STSLSPFYLR   PPSFLRAPSW   FDTGLSEMRL   EKDRFSVNL VKHFSPEELK   VKVLGDVIEV   HGKHEERQDE   HGFISREFHR KYRIPADVDP   LTTITSSLSSD   GVLTVNGPRK   QVSGPERTIP ITREEKPAVT   AAPKK           </pre> |
| <b>Appearance</b>              | Lyophilized powder.   |
| <b>Formulation</b>             | Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4 or 50 mM Tris-HCL, 300 mM NaCL, pH 8.0.  |
| <b>Endotoxin Level</b>         | <1 EU/µg, determined by LAL method.   |
| <b>Reconstitution</b>          | It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).                               |
| <b>Storage &amp; Stability</b> | Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.                 |
| <b>Shipping</b>                | Room temperature in continental US; may vary elsewhere.   |

### DESCRIPTION

|                   |  |
|-------------------|--|
| <b>Background</b> | CRYAB regulates inflammatory response in intestinal mucosa by inhibiting IKKβ-mediated signaling and may serve as a novel therapeutic approach in the inflammatory bowel disease (IBD). Enforced expression of CRYAB suppressed expression of proinflammatory cytokines (e.g., TNF-α, IL-6, IL-1β, and IL-8) via inhibiting the IKK complex formation, whereas lack of CRYAB expression markedly enhanced proinflammatory responses <sup>[1]</sup> . |
|-------------------|--|

---

## REFERENCES

---

[1]. Weimin Xu, et al. Small heat shock protein CRYAB inhibits intestinal mucosal inflammatory responses and protects barrier integrity through suppressing IKK $\beta$  activity. *Mucosal Immunol.* 2019 Nov;12(6):1291-1303.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA